A new clinical trial suggests retatrutide could become a major breakthrough treatment for obesity and Type 2 diabetes.
A new Phase 3 clinical trial by Eli Lilly and Company found that its experimental drug retatrutide helped adults with Type 2 diabetes lose significant weight while improving blood sugar control.
Researchers said patients taking the highest dose lost an average of 36.6 pounds, or 16.8% of their body weight, after 40 weeks of treatment. The once-weekly injectable medication also reduced A1C levels by up to 2.0%, a key measure used to monitor long-term blood sugar levels.
Retatrutide for Type 2 diabetes works differently from existing weight loss drugs because it targets three hormone receptors — GIP, GLP-1 and glucagon. This “triple agonist” approach may help reduce appetite, improve blood sugar control and increase the body’s energy use.
The study included 537 adults with Type 2 diabetes whose blood sugar levels were not properly controlled through diet and exercise alone. Researchers said many participants were still losing weight by the end of the trial. A suggestion that stronger results may still be possible.
The findings come as demand for GLP-1 medications such as Ozempic, Wegovy and Zepbound continues to grow globally.
Common side effects reported during the trial included nausea, diarrhea and vomiting, especially during dose increases. Researchers are also monitoring reports of increased heart rate and skin discomfort.
RELATED: https://www.who.int/news-room/fact-sheets/detail/diabetes
Retatrutide has not yet been approved by the U.S. Food and Drug Administration. Eli Lilly stated that it could seek regulatory approval in late 2027 or early 2028, pending the continuation of positive results.
The latest results position retatrutide as a closely watched experimental drug in the growing obesity and diabetes treatment market.
READ ALSO: https://alo360.net/dr-congo-ebola-outbreak-spreading-faster-who/